In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Hyperion buys Andromeda for cash and stock

Executive Summary

Orphan disease-focused Hyperion Therapeutics Inc. acquired private Israeli firm Andromeda Biotech Ltd., paying $12.5mm in cash and issuing 312,869 common shares worth $7.87mm (based on the market average of $25.14).
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash
    • Acquisition of Private Biotech
    • Payment Includes Stock
    • Intra-Biotech Deal
    • Includes Earnout

Related Companies

Advertisement
UsernamePublicRestriction

Register